Asia Pacific Biosimilars Market Analysis: China vs S.Korea (2024–2032)

China and South Korea continued to shape the competitive landscape of the Asia Pacific Biosimilars Market, with both countries demonstrating strong upward momentum through ***. China was valued at USD ***.*** million in *** and is projected to increase to USD ***.*** million by ***, supported by large-scale manufacturing capacity, expanding regulatory approvals, and strong domestic demand across oncology and autoimmune therapies. South Korea, a global biosimilars innovation hub, was valued at USD *** million in *** and is projected to reach USD ***.*** million by ***, driven by its advanced R&D ecosystem, leading biopharma manufacturers, and a progressive export-oriented pipeline.